Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 7/20 | 0.82 |
| ▸ | KCNK9 | Q9NPC2 | 7/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | GRM5 | P41594 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11795078 | 0.89 | KCNK3 (0.73) | KCNK3KCNK9MAPK1KMT2APOLB | |
| SCHEMBL31311158 | 0.86 | KCNK3 (0.72) | KCNK3KCNK9MAPK1KMT2AMAPT | |
| SCHEMBL2362772 | 0.85 | KMT2A (0.82) | KCNK3KCNK9MAPK1KMT2APOLB | |
| SCHEMBL28197272 | 0.85 | NR1H4 (0.69) | KCNK3KCNK9MAPK1KMT2ARAB9A | |
| SCHEMBL1505333 | 0.84 | RAB9A (0.60) | KCNK3KCNK9MAPK1KMT2APOLB | |
| SCHEMBL7179615 | 0.84 | GRM5 (0.63) | KCNK3KCNK9KMT2APOLBGRM5 | |
| SCHEMBL2912793 | 0.84 | KCNK3 (0.62) | KCNK3KCNK9MAPK1KMT2APOLB | |
| SCHEMBL16676736 | 0.83 | POLB (0.76) | KCNK3KCNK9MAPK1KMT2APOLB | |
| SCHEMBL28826743 | 0.83 | KCNK3 (0.83) | KCNK3KCNK9MAPK1KMT2APOLB | |
| SCHEMBL19642749 | 0.83 | KCNK3 (1.00) | KCNK3KCNK9MAPK1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310944-B2 | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2025-05-27 | — | — | US | disclosed |
| US-20230165833-A1 | Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use Thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2023-06-01 | — | — | US | disclosed |
| WO-2021042410-A1 | SELECTIVE BUTYRYLCHOLINESTERASE INHIBITOR OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 中国药科大学 | 2021-03-11 | — | — | WO | disclosed |
| CN-110627767-B | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国药科大学 | 2020-08-25 | — | — | CN | disclosed |
| CN-110627767-A | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and application thereof | 中国药科大学 | 2019-12-31 | — | — | CN | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165833-A1 | Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use Thereof | BCHE, ACHE, BACE1 | KCNK3 1980/4885KCNK9 545/4885MAPK1 1357/4885 |
| US-12310944-B2 | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof | BCHE, ACHE, BACE1 | KCNK3 2135/4885KCNK9 679/4885MAPK1 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.